↓ Skip to main content

Alzheimer Disease

Overview of attention for book
Cover of 'Alzheimer Disease'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Development of Drugs for Alzheimer Therapy: A Decade of Progress
  3. Altmetric Badge
    Chapter 2 Epidemiology of AD: Impact on the Treatment
  4. Altmetric Badge
    Chapter 3 Neuropathological Bases of Alzheimer Disease, Implications for Treatment
  5. Altmetric Badge
    Chapter 4 Amyloid Deposition as the Central Event in the Etiology and Pathogenesis of Alzheimer’s Disease
  6. Altmetric Badge
    Chapter 5 Role of Abnormal Phosphorylation of Tau in Neurofibrillary Degeneration: Implications for Alzheimer Therapy
  7. Altmetric Badge
    Chapter 6 Olfactory Bulb Involvement in AD: An Early Change
  8. Altmetric Badge
    Chapter 7 Alzheimer Disease -- A Spirochetosis?
  9. Altmetric Badge
    Chapter 8 Beta Amyloid (Aβ) as a Therapeutic Target in Alzheimer’s Disease
  10. Altmetric Badge
    Chapter 9 Regulation of APP Processing by First Messengers
  11. Altmetric Badge
    Chapter 10 In Vitro Production of Amyloid β-Protein: A Route to the Mechanism and Treatment of Alzheimer’s Disease
  12. Altmetric Badge
    Chapter 11 Apolipoprotein E and Alzheimer’s Disease: Therapeutic Implications
  13. Altmetric Badge
    Chapter 12 Apolipoprotein E4 and Cholinergic Dysfunction in Alzheimer’s Disease
  14. Altmetric Badge
    Chapter 13 Butyrylcholinesterase in Alzheimer’s Disease
  15. Altmetric Badge
    Chapter 14 Modulating Cholinergic Neurotransmission Through Transgenic Overexpression of Human Cholinesterases
  16. Altmetric Badge
    Chapter 15 Structure-Function Relationships in The Binding of Reversible Inhibitors in the Active-Site Gorge of Acetylcholinesterase
  17. Altmetric Badge
    Chapter 16 Cholinergic Changes and Synaptic Alterations in Alzheimer’s Disease
  18. Altmetric Badge
    Chapter 17 Introduction to Cholinesterase Inhibitors Used in Alzheimer’s Disease Therapy
  19. Altmetric Badge
    Chapter 18 A Pharmacodynamic Strategy to Optimize the Clinical Response to Eptastigmine (MF-201)
  20. Altmetric Badge
    Chapter 19 Eptastigmine (MF-201). A Double-Blind, Placebo-Controlled, Clinical Trial in Alzheimer Disease Patients
  21. Altmetric Badge
    Chapter 20 Cognition Improvement by Oral Huperzine A: A Novel Acetylcholinesterase Inhibitor
  22. Altmetric Badge
    Chapter 21 In Vitro and In Vivo Effects of a Dual Inhibitor of Acetylcholinesterase and Muscarinic Receptors, CI-1002
  23. Altmetric Badge
    Chapter 22 Effects of Novel Cholinesterase Inhibitors Based on the Mechanism of Enzyme Inhibition
  24. Altmetric Badge
    Chapter 23 Biochemistry, Pharmacokinetics and Pharmacodynamics of MDL 73,745: A Potent and Selective Inhibitor of Acetylcholinesterase
  25. Altmetric Badge
    Chapter 24 Clinical Experience with MDL 73,745; Pharmacokinetics, Pharmacodynamics, and Clinical Tolerance in Normal Volunteers
  26. Altmetric Badge
    Chapter 25 Galanthamine in Alzheimer’s Disease
  27. Altmetric Badge
    Chapter 26 Tacrine: An Overview of Efficacy in Two Parallel Group Studies
  28. Altmetric Badge
    Chapter 27 Clinical Update of Velnacrine Research
  29. Altmetric Badge
    Chapter 28 Second and Third Generation Cholinesterase Inhibitors: From Preclinical Studies to Clinical Efficacy
  30. Altmetric Badge
    Chapter 29 Second and Third Generation Cholinesterase Inhibitors: Clinical Aspects
  31. Altmetric Badge
    Chapter 30 Nicotinic Receptors in Human Brain
  32. Altmetric Badge
    Chapter 31 Development of Nicotinic Agonists for the Treatment of Alzheimer’s Disease
  33. Altmetric Badge
    Chapter 32 The Role of Nicotinic Systems in the Cognitive Disorder of Alzheimer’s Disease
  34. Altmetric Badge
    Chapter 33 ABT-418: A Novel Cholinergic Channel Activator (ChCA) for the Potential Treatment of Alzheimer’s Disease
  35. Altmetric Badge
    Chapter 34 Nicotine, Catecholamines and Cognitive Enhancement
  36. Altmetric Badge
    Chapter 35 The Subunit Specific Effects of Novel Anabaseine-Derived Nicotinic Agents
  37. Altmetric Badge
    Chapter 36 Serotonin Depletion Decreases Therapeutic Effect of THA and Nicotine
  38. Altmetric Badge
    Chapter 37 Selective Signaling Via Novel Muscarinic Agonists: Implications for Alzheimer’s Disease Treatments and Clinical Update
  39. Altmetric Badge
    Chapter 38 Selective Muscarinic Agonists for Alzheimer Disease Treatment
  40. Altmetric Badge
    Chapter 39 Xanomeline: An Efficacious and Specific M1 Receptor Agonist — Preclinical Update
  41. Altmetric Badge
    Chapter 40 Xanomeline, A Specific M1 Agonist: Early Clinical Studies
  42. Altmetric Badge
    Chapter 41 CI-979/RU 35926: A Novel Muscarinic Agonist for the Treatment of Alzheimer’s Disease
  43. Altmetric Badge
    Chapter 42 Choline Metabolism, Membrane Phospholipids, and Alzheimer’s Disease
  44. Altmetric Badge
    Chapter 43 Neurotransmitter Release Enhancement as a Possible Therapy for Neurodegenerative Diseases: Update on Linopirdine (DUP996)
  45. Altmetric Badge
    Chapter 44 Nootropic Drugs: The Gap Between Preclinical and Clinical Results
  46. Altmetric Badge
    Chapter 45 Nootropic Drugs in Alzheimer Disease Treatment. New Pharmacological Strategies
  47. Altmetric Badge
    Chapter 46 Therapeutic Efficacy of Nootropic Drugs in Alzheimer’s Disease and Age Related Cognitive Dysfunction
  48. Altmetric Badge
    Chapter 47 Toward the Repair of Cortical Synapses in Alzheimer’s Disease
  49. Altmetric Badge
    Chapter 48 Gangliosides in Alzheimer’s Disease: Experimental and Clinical Data
  50. Altmetric Badge
    Chapter 49 Excitatory Transmitter Neurotoxicity and Alzheimer’s Disease
  51. Altmetric Badge
    Chapter 50 Free Intracellular Calcium in Aging and Alzheimer’s Disease
  52. Altmetric Badge
    Chapter 51 Nitric Oxide Synthase in a Lesion Model of Alzheimer’s Disease
  53. Altmetric Badge
    Chapter 52 Antioxidant Drugs as Neuroprotective Agents
  54. Altmetric Badge
    Chapter 53 Immune Mechanisms in Senile Plaque Formation
  55. Altmetric Badge
    Chapter 54 Inflammatory Pathology in Alzheimer’s Disease
  56. Altmetric Badge
    Chapter 55 Aluminum Chelation Therapy of Alzheimer’s Disease
  57. Altmetric Badge
    Chapter 56 In Vitro Evidence for the Use of Antioxidants in Alzheimer’s Disease
  58. Altmetric Badge
    Chapter 57 Pharmacologic Management of Agitation and Depression in Dementia
  59. Altmetric Badge
    Chapter 58 Treatment with Serotonergic Drugs of Emotional Disturbances in Patients with Dementia Disorders
  60. Altmetric Badge
    Chapter 59 Glutamatergic Hypoactivity in Alzheimer’s Disease: Investigative and Therapeutic Perspectives
  61. Altmetric Badge
    Chapter 60 Disturbances of Gait in Patients with Dementia
  62. Altmetric Badge
    Chapter 61 The Centrally Cholinodeficient Animal as a Model of Alzheimer’s Disease (AD)
  63. Altmetric Badge
    Chapter 62 Role of the Carboxyterminus of the Alzheimer Amyloid Protein Precursor in Alzheimer’s Disease Neurodegeneration
  64. Altmetric Badge
    Chapter 63 Neurofilament Pathology in Animal Models for Alzheimer’s Disease
  65. Altmetric Badge
    Chapter 64 Transgenic Mice as a Model of Alzheimer’s Disease
  66. Altmetric Badge
    Chapter 65 Aged Non-Human Primates as Models of β-Amyloidoses
  67. Altmetric Badge
    Chapter 66 Model Studies of the Role of Anti-Neurofilament Antibodies in Neurodegeneration in Alzheimer’s Disease
  68. Altmetric Badge
    Chapter 67 Use of PET Technique to Monitor Effect of Drugs in Alzheimer Disease Treatment
  69. Altmetric Badge
    Chapter 68 Positron Emission Tomography with [11C]-Methyltacrine and [11C]-Physostigmine
  70. Altmetric Badge
    Chapter 69 Use of SPECT in Early Diagnosis and to Monitor the Effect of Drugs in Alzheimer Disease
  71. Altmetric Badge
    Chapter 70 Nicotinic Stimulation of Anterior Regional Cerebral Glucose Metabolism in Alzheimer’s Disease: Preliminary Study with Transdermal Patches
  72. Altmetric Badge
    Chapter 71 Minimal Efficacy Criteria for Medications in Alzheimer Disease
  73. Altmetric Badge
    Chapter 72 Clinical Testing of New Drugs for Efficacy in Alzheimer’s Disease
  74. Altmetric Badge
    Chapter 73 Instruments for Measuring the Efficacy of Treatments for Alzheimer’s Disease
  75. Altmetric Badge
    Chapter 74 Psychometric Strengths and Weaknesses of the Alzheimer Disease Assessment Scale in Clinical Testing: Recommendations for Improvements
  76. Altmetric Badge
    Chapter 75 Validation of Informant-Based Cognitive Assessment for Use in Autopsy
  77. Altmetric Badge
    Chapter 76 Socio-Economic Aspects of Alzheimer’s Disease Treatment
  78. Altmetric Badge
    Chapter 77 Autonomy in Alzheimer Disease
  79. Altmetric Badge
    Chapter 78 Economic Analysis of Alzheimer’s Disease in Outpatients: Impact of Symptom Severity
  80. Altmetric Badge
    Chapter 79 AD Treatment: The Future
  81. Altmetric Badge
    Chapter 80 Therapeutic Strategies in Alzheimer’s Disease
  82. Altmetric Badge
    Chapter 81 New Strategies for Alzheimer’s Disease Treatment: Pleiotropic Drugs and Multifactorial Intervention
Overall attention for this book and its chapters
Altmetric Badge

Mentioned by

twitter
2 X users
facebook
1 Facebook page

Citations

dimensions_citation
69 Dimensions

Readers on

mendeley
1 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Alzheimer Disease
Published by
Birkhäuser Boston, January 1994
DOI 10.1007/978-1-4615-8149-9
ISBNs
978-1-4615-8151-2, 978-1-4615-8149-9
Editors

Ezio Giacobini, Robert E. Becker

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 1 Mendeley reader of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
France 1 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 1 100%
Readers by discipline Count As %
Chemistry 1 100%